420 related articles for article (PubMed ID: 33256581)
1. Elucidating the Risk Factors for Progression from Amyloid-Negative Amnestic Mild Cognitive Impairment to Dementia.
Kim HJ; Lee JH; Cheong EN; Chung SE; Jo S; Shim WH; Hong YJ
Curr Alzheimer Res; 2020; 17(10):893-903. PubMed ID: 33256581
[TBL] [Abstract][Full Text] [Related]
2. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
3. The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HJ; Oh JS; Lim JS; Lee S; Jo S; Chung EN; Shim WH; Oh M; Kim JS; Roh JH; Lee JH;
Alzheimers Res Ther; 2022 Jul; 14(1):93. PubMed ID: 35821150
[TBL] [Abstract][Full Text] [Related]
4. The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.
Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kwon M; Kim JS; Kim BJ; Lee JH
Eur J Neurol; 2021 May; 28(5):1520-1527. PubMed ID: 33559375
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis.
Botha H; Mantyh WG; Murray ME; Knopman DS; Przybelski SA; Wiste HJ; Graff-Radford J; Josephs KA; Schwarz CG; Kremers WK; Boeve BF; Petersen RC; Machulda MM; Parisi JE; Dickson DW; Lowe V; Jack CR; Jones DT
Brain; 2018 Apr; 141(4):1201-1217. PubMed ID: 29538658
[TBL] [Abstract][Full Text] [Related]
6. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
[TBL] [Abstract][Full Text] [Related]
7. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease.
Douaud G; Menke RA; Gass A; Monsch AU; Rao A; Whitcher B; Zamboni G; Matthews PM; Sollberger M; Smith S
J Neurosci; 2013 Jan; 33(5):2147-55. PubMed ID: 23365250
[TBL] [Abstract][Full Text] [Related]
8. Early Impairment in the Ventral Visual Pathway Can Predict Conversion to Dementia in Patients With Amyloid-negative Amnestic Mild Cognitive Impairment.
Kim HJ; Cheong EN; Jo S; Lee S; Shim WH; Kang DW; Kwon M; Kim JS; Lee JH
Alzheimer Dis Assoc Disord; 2021 Oct-Dec 01; 35(4):298-305. PubMed ID: 34132669
[TBL] [Abstract][Full Text] [Related]
9. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
11. Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.
Coutinho AM; Porto FH; Duran FL; Prando S; Ono CR; Feitosa EA; Spíndola L; de Oliveira MO; do Vale PH; Gomes HR; Nitrini R; Brucki SM; Buchpiguel CA
Alzheimers Res Ther; 2015 Sep; 7(1):58. PubMed ID: 26373380
[TBL] [Abstract][Full Text] [Related]
12. Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests.
Bahar-Fuchs A; Villemagne V; Ong K; Chetélat G; Lamb F; Reininger CB; Woodward M; Rowe CC
J Alzheimers Dis; 2013; 33(2):451-62. PubMed ID: 23011220
[TBL] [Abstract][Full Text] [Related]
13. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
14. A biomarker study in long-lasting amnestic mild cognitive impairment.
Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
[TBL] [Abstract][Full Text] [Related]
16. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
[TBL] [Abstract][Full Text] [Related]
18. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.
Cho H; Choi JY; Hwang MS; Kim YJ; Lee HM; Lee HS; Lee JH; Ryu YH; Lee MS; Lyoo CH
Ann Neurol; 2016 Aug; 80(2):247-58. PubMed ID: 27323247
[TBL] [Abstract][Full Text] [Related]
19. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
[TBL] [Abstract][Full Text] [Related]
20. Association between fully automated MRI-based volumetry of different brain regions and neuropsychological test performance in patients with amnestic mild cognitive impairment and Alzheimer's disease.
Arlt S; Buchert R; Spies L; Eichenlaub M; Lehmbeck JT; Jahn H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):335-44. PubMed ID: 22940716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
